Connect with us

News

COVID-19 Impact and Recovery Analysis – Global Medical Thermometers Market 2020-2024 | Evolving Opportunities with American Diagnostic Corp. and Ansell Ltd. | Technavio

gbafNews28

The medical thermometers market is poised to grow by USD 104.82 million during 2020-2024 progressing at a CAGR of over 8% during the forecast period.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis

The report on the medical thermometers market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by frequent outbreak of epidemics.

The medical thermometers market analysis includes product segment and geography landscape. This study identifies the growing availability of advanced medical thermometers as one of the prime reasons driving the medical thermometers market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters

The medical thermometers market covers the following areas:

Medical Thermometers Market Sizing Medical Thermometers Market Forecast Medical Thermometers Market Analysis

Companies Mentioned

  • American Diagnostic Corp.
  • Ansell Ltd.
  • Beurer GmbH
  • Briggs Corp.
  • Citizen Watch Co. Ltd.
  • Exergen Corp.
  • EASYTEM Co. Ltd.
  • OMRON Corp.
  • Paul Hartmann AG
  • Tecnimed Srl

Key Topics Covered:

Executive Summary

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 – 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Digital thermometers – Market size and forecast 2019-2024
  • Liquid filled thermometers – Market size and forecast 2019-2024
  • Market opportunity by Product

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America – Market size and forecast 2019-2024
  • APAC – Market size and forecast 2019-2024
  • Europe – Market size and forecast 2019-2024
  • South America – Market size and forecast 2019-2024
  • MEA – Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers “ Demand led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • American Diagnostic Corp.
  • Ansell Ltd.
  • Beurer GmbH
  • Briggs Corp.
  • Citizen Watch Co. Ltd.
  • Exergen Corp.
  • EASYTEM Co. Ltd.
  • OMRON Corp.
  • Paul Hartmann AG
  • Tecnimed Srl

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

     

About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: www.technavio.com/

News

Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited

gbafNews28

Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (Takeda) in Asia Pacific, igniting efforts to strengthen its R&D capability in the global small molecule pharmaceuticals business.

In June, the firms announced an agreement under which Celltrion would acquire 18 “Primary Care” product assets in the Asia Pacific area for a total of USD 278 million inclusive of milestone payments from Takeda. Celltrion proceeded with the acquisition process through its newly established subsidiary in Singapore, “Celltrion Asia Pacific Pte, Ltd.”1 (“Celltrion APAC”).

Upon completion of the acquisition, Celltrion APAC will assume the ownership of the rights to patents, trademarks, and sales of 18 products sold in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia.

The 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Edarbi (hypertension) which were developed for global market, as well as OTC (Over-the-counter) products well known to consumers such as Whituben (cold remedy). Nesina and Edarbi in particular are expected to contribute to a stable revenue growth as the product patents will be protected until 2026 and 2027, respectively.

Celltrion Pharm, a Celltrion subsidiary, will be a primary domestic distributor, while Celltrion Healthcare will distribute internationally, leveraging its sales networks in Southeast Asia and Australia. Celltrion has entered into a manufacturing and supply agreement with Takeda who will continue to manufacture the divested products for stable product supply and some of the products for local and international market will be manufactured at Celltrion Pharms cGMP production facilities in future.

The acquisition provides Celltrion group an opportunity to strengthen its small molecule pharmaceutical product portfolio and progress towards a market leading position as a global biopharmaceutical company.

Celltrion group also expects this transaction to help position itself as a stable supplier of high-quality, made-in-Korea original drugs and contribute to the reinforced financial strength of the national health system.

Based on its own R&D capacities and to-be acquired product patents, Celltrion plans to speed up the development of new medicines such as extended-release drugs and compound drugs, as well as biosimilar insulins to complete the portfolio of diabetic and hypertensive pipelines.

Celltrion CEO Kee Woosung said “With the successful acquisition of select primary care and OTC product assets from Takeda in Asia Pacific Celltrion has set an important opportunity to develop additional new drugs and expand its market share in the region,” and “Celltrion will also do its best to secure a leading position in the Asia Pacific market and provide high quality medical products in the region.”

About Celltrion, Inc

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and ECs approval for Inflectra and Remsima, respectively, which is the worlds first mAb biosimilar to receive approval from a regulatory agency in a developed country. Also Celltrion received FDA and ECs approval for Truxima and Herzuma. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines.


1 Celltrion Asia Pacific PtE. Ltd.

Celltrion, Inc.

Eunyoung Lee, +82 32 850 4384

[email protected]

Or

Tae-Gyun Kim, +82 32 850 5136

[email protected]

Continue Reading

News

Arcturus Therapeutics to Present at Upcoming Investor Conference

gbafNews28

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at Piper Sandlers 32nd Annual Virtual Healthcare Conference:

The Road Ahead for COVID-19 Vaccines: What We Know and Questions Still to be Answered into 2021

Panel Presentation Date: Tuesday, Dec 1, 2020 Time: 10:00 a.m. ET

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR„¢ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, and Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus technologies are covered by its extensive patent portfolio (200 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

IR and Media Contacts

Arcturus Therapeutics

Neda Safarzadeh

(858) 900-2682

[email protected]

Kendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

[email protected]

Continue Reading

News

Diamond S Shipping Inc. Comments on an Incident Involving One of Its Vessels

gbafNews28

Diamond S Shipping Inc. (NYSE: DSSI) (Diamond S or the Company) announced the receipt of an incident report involving a kidnapping on one of its product tanker vessels, the Agisilaos, as it was approaching the port of Lome, Togo on November 29, 2020.  The vessel is managed and crewed by Capital Ship Management Corp. (˜Capital) who informed Diamond S about the kidnapping of four crew members. The Company confirms that there were 22 seafarers aboard when the attack occurred.  There have been no reports of injuries at this time. All appropriate authorities have been notified and Diamond S is fully supporting Capital as they respond to this situation. Diamond S will not comment further on these operational issues to avoid potentially jeopardizing the safety of the crew members being held or prolonging their stay in captivity.

About Diamond S Shipping Inc.

Diamond S Shipping Inc. (NYSE Ticker: DSSI) owns and operates 66 vessels on the water, including 15 Suezmax vessels, one Aframax and 50 medium-range (MR) product tankers. Diamond S Shipping is one of the largest energy shipping companies providing seaborne transportation of crude oil and refined petroleum products in the international shipping markets.  The Company is headquartered in Greenwich, CT.  More information about the Company can be found at www.diamondsshipping.com.

Investor Relations Inquiries:

Robert Brinberg

Tel: +1-212-517-0810

E-mail: [email protected]

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News12 mins ago

Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited

Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (Takeda) in Asia Pacific,...

gbafNews28 gbafNews28
News12 mins ago

Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) today announced the completion of its previously-announced sale of a portfolio of select products...

gbafNews28 gbafNews28
News12 mins ago

Diamond S Shipping Inc. Comments on an Incident Involving One of Its Vessels

Diamond S Shipping Inc. (NYSE: DSSI) (Diamond S or the Company) announced the receipt of an incident report involving a...

gbafNews28 gbafNews28
News12 mins ago

Arcturus Therapeutics to Present at Upcoming Investor Conference

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development...

gbafNews28 gbafNews28
News14 mins ago

KBRA Assigns Ratings to Sunnova Sol II Issuer, LLC, Series 2020-2

Kroll Bond Rating Agency (KBRA) assigns ratings to two note classes issued by Sunnova Sol II Issuer, LLC, Series 2020-2....

gbafNews28 gbafNews28
News22 mins ago

Laura J. Schumacher Joins CrowdStrike’s Board of Directors

CrowdStrike Holdings, Inc. (Nasdaq: CRWD), a leader in cloud-delivered endpoint and workload protection, today announced the appointment of Laura J....

gbafNews28 gbafNews28
News28 mins ago

Cornerstone Community Bancorp Announces Stock Repurchase Plan

Cornerstone Community Bancorp, (OTC Pink: CRSB), the parent company of Cornerstone Community Bank, announced today that its Board of Directors...

gbafNews28 gbafNews28
News42 mins ago

VIQ Solutions Reports Third Quarter Results

VIQ Solutions Inc. (“VIQ” or the “Company”) (TSX Venture Exchange: VQS and OTC Markets: VQSLF) a global provider of secure,...

gbafNews28 gbafNews28
News42 mins ago

Spectra7 Announces Third Quarter Financial Results

(TSX-V:SEV) Spectra7 Microsystems Inc. (Spectra7 or the Company), a leading provider of high-performance analog semiconductor products for broadband connectivity markets,...

gbafNews28 gbafNews28
News42 mins ago

Oshkosh Corporation to Present at the Credit Suisse 8th Annual Virtual Industrials Conference

Oshkosh Corporation (NYSE:OSK), a leading innovator of mission-critical vehicles and essential equipment, announced today that it will present at the...